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T
he number of immunocompromised patients is increasing worldwide, and these individuals are at high risk for acquiring severe microbial infections, which are frequently caused by Candida spp. (1) . Most commonly, cases of bloodstream infections with Candida spp. (candidemia) are related to surgery, intensive care, solid tumors, or hematological malignancies (2) . The mortality rate that is directly attributable to candidemia ranges from 5 to 71%, depending on the clinical cohort (3, 4) . Particularly high mortalities occur in patients with solid tumors (65%) and hematologic malignancies (46%) (5) . Severe mycoses are frequently caused by species of the Candida clade, such as C. albicans, C. dubliniensis, and C. glabrata (6, 7) . Although these species cause severe invasive infections in immunocompromised persons, they are also common as part of the commensal flora on mucous membranes. C. albicans is the most common human fungal pathogen and is able to switch back and forth from yeast to hyphal growth. This revertible morphogenetic switch plays a key role in the virulence of C. albicans (8) (9) (10) . C. albicans and C. dubliniensis are phylogenetically closely related, sharing a polymorphic and obligatory diploid nature (11) . However, C. dubliniensis differs in virulence-associated gene families, such as the agglutinin-like sequences (ALS), which render C. dubliniensis less virulent than C. albicans (12) . Nevertheless, C. dubliniensis causes candidemia associated with equally high mortality rates (13) . C. glabrata is a haploid yeast and is often referred to as the second most frequent yeast causing candidemia (7) . Importantly, C. glabrata has decreased in vitro susceptibility against fluconazole. This suggests an increased risk for C. glabrata infections due to prophylactic fluconazole treatment of patients at high risk for invasive candidiasis (14) .
Despite the urgent requirement for efficient antifungal therapies, the available standard antifungal drugs (SADs) are few and have a restricted set of fungal targets. Polyenes, azoles, allylamines, morpholines, antimetabolites, and echinocandins are the 6 major antifungal drug categories (15) . The first three directly or indirectly target ergosterol, a major fungal membrane component. The long-term use of drugs that target ergosterol, such as fluconazole or amphotericin B, can result in renal and liver toxicity (16) . The following two categories interfere with DNA/RNA synthesis. Antimetabolites are known human carcinogens, causing liver toxicity and bone marrow depression and thus are less frequently used (16, 17) . The relatively newly introduced echinocandins inhibit 1,3-␤-glucan synthesis in the cell wall and have few notable side effects. The emergence of echinocandin-resistant isolates, however, is a cause for clinical concern (18) . Taken together, there is a demand for new antifungal substances, preferably those with novel fungal targets.
The scope of this study was to find previously unknown antifungal activities in agents from the Enzo drug library and the Institute for Molecular Medicine Finland (FIMM) oncology collection (19) . We rationalized that knowledge about antifungal activity against common human fungal pathogens in off-patent drugs from the Enzo library should be beneficial to increase the treatment possibilities for severe mycoses. Moreover, we screened the FIMM oncology collection, which contains antineoplastic drugs, with the purpose of identifying agents that affect both primary immune-suppressive cancer disease and a possible secondary Candida infection, which occurs frequently in cancer patients. This additional information is beneficial for patients if a choice of therapy is possible. We performed the screen with C. albicans and confirmed antifungal activities for 19 drugs that have been previously described for their antimycotic capacities, approving the validity of our methods. We identified 7 novel agents previously unknown to inhibit the growth of C. albicans (Table 1) . Notably, the susceptibility of C. albicans to SADs was comparable to the antifungal effect of the seven agents identified in this screen.
MATERIALS AND METHODS
Drugs and fungal strains. The in vitro susceptibility of C. albicans strain SC5314 was tested against 844 drugs from the Enzo FDA-approved drug library (640 drugs) and the FIMM oncology collection (19) (FDA-approved anticancer drugs [n ϭ 119] and preclinical compounds [n ϭ 85]). Thirteen FDA-approved antifungal drugs, 12 of which were active against C. albicans SC5314, and five nonantifungal drugs with antifungal activity served as controls. The screen was performed with C. albicans SC5314, and hits were further confirmed with the type strains C. dubliniensis CD36/CBS7987 and C. glabrata ATCC 90030, as well as with unrelated clinical strains of C. albicans UBC3-7922, C. glabrata UCB3-7268, and C. dubliniensis UCB-3892 from the strain collection of Norrland's University Hospital, Umeå, Sweden.
Media and antifungal microdilution testing. Cell concentration and drug microdilution analyses were performed according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, with modifications (20) . Candida yeast cells were grown overnight at 30°C with shaking in yeast peptone medium plus 2% glucose (YPD). Subcultures of 10 7 cells/ml in YPD grew for 4 h at 30°C. Drugs in the amounts of 15 to 150 nl from the Enzo and FIMM oncology collections were distributed by a liquid handling platform (Labcyte Echo 550 acoustic dispenser) in black 96-well plates with clear bottoms in six different concentrations from 0.17 nM to 10 M. Subsequently, 50 l RPMI 1640 was added to each well and the start plates were shaken (30 rpm) prior to the assay for 1 h to ensure equal distribution of the agents within the well. The yeast suspension, 100 l of 5 ϫ 10 5 cells/ml in RPMI 1640 without phenol red, and 10 mM HEPES (Lonza) were transferred to the 96-well plates containing medium and agents using a robotic device (Matrix WellMate; Thermo Scientific), resulting in a final volume of 150 l in each well. The plates were incubated at 37°C, 5% CO 2 , for 6 or 24 h.
Determination of fungal growth using absorbance. The growth of C. albicans SC5314 was analyzed using a microdilution plate assay according to EUCAST recommendations (20) . One-hundred-microliter suspensions of yeasts (5 ϫ 10 5 cells/ml) in RPMI 1640 were incubated in the presence or absence of drugs in a total volume of 150 l at 37°C, 5% CO 2 , for 6 h and 24 h. The optical densities at 450 nm (OD 450 ) in the plates were determined using a plate reader (Tecan Infinite F200). ODs of Ͻ0.1 for 6 h and 0.2 for 24 h for the 100% growth control were considered to represent poor growth and were not taken into account for the evaluation. As described above, 100% and 0% growth controls were included with every plate. All assays were performed at least as two biological replicates in triplicate (n ϭ 2 [3] ).
Determination of fungal viability using ATP levels. In order to determine the viability of the C. albicans, C. glabrata, and C. dubliniensis strains, the CellTiter-Glo luminescent cell viability kit (Promega) was used. One hundred-microliter suspensions of yeasts (5 ϫ 10 5 cells/ml) in RPMI 1640 were incubated in the presence or absence of drugs in a total volume of 150 l at 37°C, 5% CO 2 , for 6 h and 24 h. An equal volume of the CellTiter-Glo reagent was added to the medium and incubated for 15 min at room temperature with shaking at 900 rpm. The luminescent signals after 6 h and 24 h were detected using a luminometer (Tecan Infinite F200). The resulting signal intensity corresponds to ATP amounts and thus to the number of viable microbial cells upon drug exposure. In all 96-well plates, 100% and 0% growth controls were included as microbes plus dimethyl sulfoxide (DMSO) (0.1%) and microbes plus benzethonium chloride (BzCl) (100 M), respectively. All assays were performed at least as two biological replicates in triplicate (n ϭ 2 [3] ).
Microscopic analysis of morphological changes occurring upon drug treatment. For a morphological analysis of C. albicans SC5314 treated with antifungal agents (1 M), an IncuCyte automated microscope was used (Essen Bioscience). The plates were incubated at 37°C under 5% CO 2 . After the indicated time points, prior to analysis, the fungi were fixed with 2% paraformaldehyde (PFA) and phase-contrast images were captured. In this study, 4 pictures per well were taken from two biological and three technical replicates.
Statistical and data analysis. Percent growth inhibition (% Inh ) was calculated from the ATP and OD measurements resulting from the mean values from all biological replicates, using the equation % Inh ϭ 100 Ϫ (value sample /value control ) ϫ 100. The % Inh values (y axis) were plotted against the drug concentration (x axis), and the according trend line of the dose-response curve was defined and the resulting linear equation was applied to calculate the MICs using Microsoft Office Excel 2007. The MIC was the lowest drug concentration resulting in Ն50% growth inhibition compared to that of the drug-free control according to the EUCAST guidelines for flucytosine, azole antifungal agents, and echinocandins (20) . Additionally, we defined MIC 0.3 as the lowest drug concentration resulting in Ն30% growth inhibition compared to that of the drug-free control.
The data were analyzed and evaluated from 3 biological replicates in triplicate (n ϭ 3 [3] ) (Tables 2 and 3) , as well as from 4 biological replicates in triplicate (n ϭ 4 [3] ) ( Table 4 ). The strains C. dubliniensis CD36/ CBS7987 and C. glabrata ATCC 90030 shown in Table 4 were analyzed in 2 biological replicates in triplicate (n ϭ 2 [3] ). The R 2 values for all doseresponse curves ranged between 0.87 and 0.92. Additionally, the coefficients of variation (the ratio of the standard deviation to the mean) expressed as a percentage (also referred to as relative standard deviation) for all biological replicates ranged from 13 to 28%.
RESULTS
Outline of the study. Our main goal was to identify antifungal activities in drugs that were designed for other purposes. Two collection libraries, Enzo and FIMM oncology, comprising a total of 844 agents, were screened for activity against C. albicans. A major challenge for screenings with C. albicans is the characteristic of the fungus to grow as hyphal filaments (8) . Filamentation complicates assessments of growth using OD, for instance, since the number of individual cells does not increase and hyphae tend to clump excessively. Therefore, we used a luciferase-based quantification of ATP to assess fungal viability. We additionally confirmed the screening results by quantifying fungal growth using OD measurements. Both methods resulted in highly comparable results for all tested drugs. Seven off-target drugs revealed to have anti-Candida activities. The screen identified a total of 26 agents that are active against C. albicans (Table 1) . Of those, 12 were SADs and 7 were off-target drugs with known antifungal activities. Additionally, the screen revealed 7 drugs from 4 different categories of therapy with previously unidentified potent anti-Candida activities (Table 2) . Two are antipsychotic (haloperidol and trifluperidol), one is used for the treatment of anemia (stanozolol), and 4 are used for cancer therapy (melengestrol acetate, megestrol acetate, tosedostat, and amonafide). Haloperidol, but not trifluperidol, has previously been identified in a chemical-genetic screen to have antimicrobial activity against Saccharomyces cerevisiae (21) . Four agents are FDA-approved drugs and 2 are anticancer agents (amonafide and tosedostat) that are currently being tested in clinical trials (22, 23) . Although it has been applied in animal husbandry, of the identified drugs, only melengestrol acetate is not currently used in humans (24) . Moreover, we identified the antipsychotic drug methiothepin maleate, which only very recently has been identified in a repurposing screen for anticryptococcal agents (25) . We used the immunosuppressant drug rapamycin and the antirheumatic drug auranofin as references for the antifungal activities of the newly identified agents (Table 2) . Interestingly, rapamycin was originally identified as an antifungal agent (26) , and gold (I) complexes, such as auranofin, have been recognized for their antimicrobial activities (27) .
We determined the MIC and MIC 0.3 values for C. albicans by OD and ATP measurements. As mentioned above, the methods resulted in highly similar values, and thus one value for each agent is presented (Table 2 ). In general, the MICs were slightly lower after 6 h than after 24 h of incubation. However, the activities of the 7 compounds against C. albicans were stable over a period of 24 h (Table 2) . Importantly, in this screen, we did not use concen- trations of Ͼ10 M (corresponding to 3 to 10 g/ml, depending on the molecular weight of the agent), since in the therapy of systemic mycoses, maximal peak blood serum concentrations above this level are unlikely to be reached. Haloperidol, trifluperidol, stanozolol, melengestrol acetate, and megestrol acetate showed MIC values of Ͻ4 g/ml. For tosedostat and amonafide, the MIC 0.3 values were determined to be 4 and 2.8 g/ml, respectively. All 7 substances displayed a dose-dependent effect on C. albicans SC5314. The antifungal activities of amonafide and tosedostat (Table 2 ) increased slowly over a wide concentration range, from approximately 3 ϫ 10 Ϫ3 g to 4 g/ml. Novel antifungal off-target drugs and SADs have similar anti-Candida activities. We next compared the antifungal activities of the 7 identified agents to 13 established SADs present in the Enzo library. Notably, the novel candidates were inhibitory against C. albicans at a level similar to those of 12 of the SADs at a concentration of 1 M, ranging from 0.3 g to 0.7 g/ml, depending on individual molecular weights (Table 3) . Terbinafine HCl, tosedostat, and amonafide had an MIC 0.3 at a concentration of Ͼ1 M. At this concentration, nystatin was the only SAD that lacked anti-Candida activity after 6 h. Additionally, five off-target drugs with previously known antifungal activities were also identified in this screen, confirming that the applied methods were suitable to identify antifungal activity against C. albicans (Table 5) .
Microscopic analysis of morphological changes in C. albicans occurring upon treatment with newly identified agents. The antifungal effects of tosedostat and amonafide were milder than those of other drugs (Tables 2 and 3) . To verify the possible effects of the selected agents identified in this study on C. albicans, we additionally performed a direct microscopic investigation of treated C. albicans (Fig. 1) . DMSO-and BzCl-treated C. albicans served as 100% and 0% growth controls, respectively (Fig. 1A and  B ). Haloperidol and trifluperidol ( Fig. 1E and G) show a very similar effect as fluconazole (Fig. 1C) . The hyphae are considerably shorter, with the tendency to form branches more frequently than with untreated control hyphae. Notably, tosedostat and amonafide ( Fig. 1F and H) caused similar morphological changes as those observed in the samples treated with rapamycin (Fig. 1D) . The hyphae are significantly shorter, with the germ tubes having a curved shape. The control hyphae, in contrast, are longer and straight. Thus, our screen identified substances with comparable effects on C. albicans morphology as the well-known antifungal agent fluconazole or the immunosuppressant drug with antifungal activity, rapamycin. This indicates that the identified agents indeed inhibit the growth of C. albicans.
Confirmation of antifungal activities of identified drugs on clinical isolates from different Candida spp. To assess whether the 7 new antifungal candidate agents were also effective against other clinical isolates of C. albicans, as well as other Candida species, we compared C. albicans SC5314 to other clinical isolates from C. albicans, C. dubliniensis, and C. glabrata (Table 4) . C. albicans SC5314 and the off-target drugs with known antifungal a The tested concentrations of off-target drugs with previously demonstrated antifungal activity used in this study were compared to concentrations used in previous studies with similar incubation times.
activity, methiothepin maleate, rapamycin, and auranofin, were included. Since the MICs calculated from the OD and ATP measurements were very similar, we exclusively applied ATP measurement.
Rapamycin was effective against all tested strains (MIC, Ͻ0.1 g/ml). The C. albicans strains SC5314 and clinical isolate UBC3-7922 were affected by the 10 agents to a similar extent (Table 4). A slightly lower level of inhibition was seen for UBC3-7922 than for SC5314. Auranofin was efficient against both C. dubliniensis strains tested. Haloperidol, in contrast, inhibited the C. dubliniensis type strain (MIC, 3.76 g/ml) but inhibited the UBC3-3892 isolate less efficiently. Together, the C. dubliniensis strains were more resistant against the tested agents than the C. albicans strains. The two C. glabrata strains were affected to an even lower extent; however, they were inhibited by 6 of the 10 agents tested. Remarkably, methiothepin maleate reached an MIC of 3.57 g/ml in both C. glabrata strains (Table 4) .
DISCUSSION
Therapy against invasive fungal infections remains a challenge in health care. Many patients in surgery, intensive care, oncology, or hematology wards suffer from bloodstream infections caused by Candida spp. However, the dreary outcomes for severe mycoses do not stem solely from a lack of efficient antifungal drugs (28) . Disease progression is also determined by the immune status of the afflicted host. Our screen aimed to identify previously unknown anti-Candida activities in drugs already in use with known pharmacokinetics. We believe that this knowledge for a large amount of available pharmaceutical agents may enable (i) the development of new applications as antimycotic therapy for these types of agents, (ii) a future evaluation of the potential synergistic effects between these drugs and SADs, and (iii) therapy for patients with a primary disease, such as cancer, with drugs that have additional known antifungal activities to reduce the risk of severe secondary mycosis. Of course, the latter is only possible in cases in which a choice between several drugs is amenable. The screening of 844 approved drugs or agents in clinical trials revealed 26 substances that are active against Candida spp., 7 of which were newly identified. We showed these antifungal activities in three independent assays, metabolic activity measurement, optical densitometry according to EUCAST guidelines, and microscopy, to validate our screening results. The indicated drugs have anti-Candida activities at 6 h and 24 h ( Table 2) . The MICs of the tested agents against C. albicans SC5314 were determined by OD and ATP measurements, and the assays correlated well. Luciferase-based quantification of ATP concentrations recorded the growth of C. albicans in a similar fashion as the tetrazolium dye XTT (data not shown). XTT has been widely used by many groups, including ours, to quantify fungal viability (29, 30) , whereas ATP quantification is more sensitive than the determination of XTT metabolism, allowing for the use of fewer fungal cells per assay. This indicates that the determination of metabolic activity is a reliable measure of antifungal activity. ATP measurement has, to our knowledge, not been used in antifungal drug screening; however, it was successfully applied in an S. cerevisiaebased small-molecule screen published in the PubChem BioAssay database (31) . We confirmed the validity of our screen by identifying the FDA-approved antifungal drugs in the Enzo library (Table 3), with the exception of nystatin. In agreement with this finding, nystatin-resistant C. albicans isolates were reported (32) (33) (34) . At a concentration of 0.3 to 0.7 g/ml, the SADs and the newly identified agents showed comparable degrees of inhibition against C. albicans, such as with fluconazole (MIC, 0.3 g/ml) and haloperidol (MIC, 0.38 g/ml). Our focus was to apply drug concentrations that are likely to be reached in human therapy, and therefore, we used maximal concentrations of 10 M. The blood plasma peak concentrations (Table 2 , C max and references) and the concentrations for C. albicans inhibition of the novel antifungal candidate agents were within a similar range. This suggests that therapeutic antifungal concentrations for the treatment of systemic mycoses are accomplishable. For the trifluperidol and methiothepin maleate, such data were not obtained. To broaden the impact of our study, we included additional Candida strains. We tested the 7 novel agents with reference strains and clinical isolates of C. albicans from bloodstream infections. The C. albicans strains showed similar susceptibilities toward all 7 novel candidate agents, confirming that our findings are valid beyond common laboratory strains. The C. dubliniensis and C. glabrata strains were more resistant against treatment with these agents (Table 4) . C. glabrata is known to be less susceptible to antifungal therapy (14) . In agreement with this, C. glabrata was less susceptible to auranofin than the other two Candida spp. Notably, methiothepin maleate and tosedostat were active against both C. glabrata strains. This possibly suggests a broad anti-Candida activity for methiothepin maleate and tosedostat.
The cellular targets of the identified drugs are known in humans. The dopaminergic drugs haloperidol and trifluperidol act on G-protein-coupled receptors (GPCRs) ( Table 6) (35, 36) . Haloperidol has previously been described as a potential antifungal agent in a S. cerevisiae-based chemical-genetic screen to identify molecular targets for off-target drugs (21) . In this screen, we identified the derivative drug trifluperidol and demonstrated the antiCandida activities of both peridols. GPCRs also exist in Candida spp.; however, the major cellular pathways targeted by dopaminergic drugs are amino acid biosynthesis and metabolism (21) . The antineoplastic agent tosedostat is an aminopeptidase inhibitor (Table 6 ) (23). The targeted cellular pathways of this drug in eukaryotic cell lines are amino acid metabolism and reduced activity of target of rapamycin (TOR) kinases (37) . Remarkably, rapamycin targets TOR kinases in C. albicans (38) , and we recorded a very similar morphological effect for tosedostat and rapamycin (Fig. 1) , indicating that the drugs might have the same target against fungi. Amonafide is a topoisomerase inhibitor (22) . It is therefore likely, though not proven, that amonafide targets topoisomerases in fungi. Gene knockout of topoisomerase II in S. cerevisiae resulted in severely attenuated DNA replication (39) . Stanozolol, melengestrol, and megestrol acetate are all pseudosteroids, and thus, their molecular targets are less predictable (Table 6).
In summary, three independent assays identified 7 novel drugs with dosage-dependent activities against C. albicans with MICs of Յ4 g/ml. This study conclusively adds a new pharmacological approach to these drugs, and more importantly, it may help physicians select antineoplastic therapeutics with the antifungal activities identified here for groups of patients that are at high risk for acquiring invasive candidiasis. 
